Caduceus Biotechnology Showcases Alzheimer’s Blood Biomarker Detection Technology at ODF’26 Japan

GM Dr. Rung-Ywan Tsai delivered an oral presentation

From June 3 to June 5, 2026, Caduceus Biotechnology Inc. participated in the ODF’26 Advance Program (International Conference on Optics-photonics Design and Fabrication) held at the Toyama International Conference Center in Japan. Representing the company, President and General Manager Dr. Rung-Ywan Tsai delivered an oral presentation, sharing the company’s latest research achievements with leading experts, researchers, and industry professionals from around the world.

The International Conference on Optics-photonics Design and Fabrication (ODF) is one of Asia’s most influential conferences in optics and photonics. Organized by the Optical Design Group of the Optical Society of Japan, the conference has been held biennially since 1998 and serves as a premier platform for academic and industrial exchange in optical design, photonics, precision manufacturing, optical systems, biomedical optics, imaging technologies, and emerging photonic applications.

During the conference, Dr. Tsai presented a technical paper entitled “Digital ELISA for Alzheimer’s Disease (AD) Blood Biomarker Detection.” The presentation highlighted Caduceus Biotechnology’s ongoing development of an innovative blood-based biomarker detection platform for Alzheimer’s disease, as well as the application of highly sensitive Digital ELISA technology for early screening and precision medicine in neurodegenerative diseases.

As global populations continue to age, Alzheimer’s disease has become a critical healthcare challenge worldwide. Caduceus Biotechnology is committed to integrating advanced optical detection technologies, biomedical engineering, and digital molecular analysis platforms to develop clinically applicable blood-testing solutions. The company aims to provide convenient and cost-effective tools for early disease detection, helping healthcare providers improve diagnostic efficiency and patient care outcomes.

The paper was accepted and selected for oral presentation within the conference’s New Technologies session, which focuses on innovative applications in biomedical optics and imaging systems. The presentation attracted significant interest from conference participants and generated valuable discussions with researchers and industry experts.

Through its participation in this international forum, Caduceus Biotechnology successfully demonstrated its technological capabilities and strengthened its visibility within the global biomedical diagnostics and optical technology communities.

In addition to the presentation, the company engaged in discussions with research institutions, industry partners, and potential investors from Japan, Europe, the United States, and other regions across Asia. These exchanges explored future opportunities for collaboration in biomedical optics, ultra-sensitive detection technologies, digital molecular analysis platforms, and the rapidly growing Alzheimer’s disease diagnostics market, laying a solid foundation for the company’s international expansion and commercialization efforts.

Caduceus Biotechnology will continue to invest in the development of highly sensitive biomarker detection technologies, expand its global partnership network, and accelerate the translation of innovative research into practical healthcare solutions. By actively participating in major international conferences and industry platforms, the company remains committed to advancing early detection technologies for Alzheimer’s disease and other critical health conditions, contributing to the future of precision medicine and global healthcare.